Huntington National Bank’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3 Hold
1
﹤0.01% 4002
2025
Q4
$3 Hold
1
﹤0.01% 3911
2025
Q3
$3 Hold
1
﹤0.01% 3942
2025
Q2
$3 Hold
1
﹤0.01% 3946
2025
Q1
$3 Hold
1
﹤0.01% 3954
2024
Q4
$3 Hold
1
﹤0.01% 3960
2024
Q3
$3 Hold
1
﹤0.01% 3951
2024
Q2
$3 Hold
1
﹤0.01% 3902
2024
Q1
$3 Hold
1
﹤0.01% 3775
2023
Q4
$3 Hold
1
﹤0.01% 3674
2023
Q3
$3 Hold
1
﹤0.01% 3651
2023
Q2
$3 Hold
1
﹤0.01% 3599
2023
Q1
$3 Hold
1
﹤0.01% 3471
2022
Q4
$3 Hold
1
﹤0.01% 3335
2022
Q3
$0 Hold
1
﹤0.01% 2633
2022
Q2
$0 Hold
1
﹤0.01% 2637
2022
Q1
$0 Hold
1
﹤0.01% 2564
2021
Q4
$0 Hold
1
﹤0.01% 2491
2021
Q3
$0 Hold
1
﹤0.01% 2217
2021
Q2
$0 Hold
1
﹤0.01% 2106
2021
Q1
$0 Hold
1
﹤0.01% 1996
2020
Q4
$0 Hold
1
﹤0.01% 1973
2020
Q3
$0 Hold
1
﹤0.01% 1918
2020
Q2
$0 Hold
1
﹤0.01% 1932
2020
Q1
$0 Hold
1
﹤0.01% 2026
2019
Q4
$0 Hold
1
﹤0.01% 2039
2019
Q3
$0 Hold
1
﹤0.01% 1944
2019
Q2
$0 Buy
+1
New ﹤0.01% 1975
2019
Q1
Sell
-1
Closed 1972
2018
Q4
$0 Hold
1
﹤0.01% 2023
2018
Q3
$0 Buy
+1
New +$4 ﹤0.01% 2011

Huntington National Bank's KERX Position: Q1 2026 in Review

Huntington National Bank held its Keryx Biopharmaceuticals Inc (KERX) position steady in Q1 2026 at 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #4002.

Huntington National Bank first reported a position in KERX in Q3 2018 and has held it in 30 quarters since. 1 fund tracked by Wall St. Rank holds KERX as of Q1 2026.

  • Huntington National Bank held 1 share of Keryx Biopharmaceuticals Inc worth $3 as of Q1 2026.
  • Huntington National Bank left its Keryx Biopharmaceuticals Inc share count unchanged in Q1 2026.
  • Keryx Biopharmaceuticals Inc made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #4002 holding.
  • Huntington National Bank first reported a position in Keryx Biopharmaceuticals Inc in Q3 2018 and has held it in 30 quarters since.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.